Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Investing Activities: 2014-2024

Historic Cash from Investing Activities for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to $162.1 million.

  • Editas Medicine's Cash from Investing Activities fell 52.88% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.6 million, marking a year-over-year decrease of 12.61%. This contributed to the annual value of $162.1 million for FY2024, which is 4445.91% up from last year.
  • According to the latest figures from FY2024, Editas Medicine's Cash from Investing Activities is $162.1 million, which was up 4,445.91% from -$3.7 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's Cash from Investing Activities registered a high of $162.1 million during FY2024, and its lowest value of -$140.5 million during FY2020.
  • Over the past 3 years, Editas Medicine's median Cash from Investing Activities value was $114.1 million (recorded in 2022), while the average stood at $90.8 million.
  • In the last 5 years, Editas Medicine's Cash from Investing Activities tumbled by 1,246.93% in 2020 and then surged by 4,445.91% in 2024.
  • Yearly analysis of 5 years shows Editas Medicine's Cash from Investing Activities stood at -$140.5 million in 2020, then spiked by 61.24% to -$54.5 million in 2021, then spiked by 309.43% to $114.1 million in 2022, then slumped by 103.27% to -$3.7 million in 2023, then surged by 4,445.91% to $162.1 million in 2024.